Microbiome-Targeted Therapeutics in Immunology
Sponsored by: GlobalData
- Microbiome Targeting
- Drug Therapies
- Human Health
Date: 27 March
Days to go: 7
Time: 4PM London/11AM New York
This expert presentation is exclusive only for GlobalData’s clients. The webinar recording and presentation will be available on the Intelligence Center. For any requests or questions about this webinar please contact email@example.com.
The human microbiome is an internal ecosystem of bacteria consisting of 10-100 trillion symbiotic bacterial cells differing from person to person. Globally, microbiome projects have been launched to understand how the microbiome impacts human health. Recent research has identified key difference between the gut and skin microbiome of a healthy individual compared with that of patients suffering from dermatological or gastrointestinal diseases. These discoveries have prompted pharmaceutical companies to begin to develop microbiome-targeted therapeutics for the treatment of immunological indications, including Crohn’s disease, ulcerative colitis, irritable bowel syndrome, acne, atopic dermatitis, and psoriasis.
Currently, there are no microbiome-targeting drug therapies approved for the treatment of gastrointestinal or dermatological indications. The industry is dependent on probiotics or antibiotics to alter the human microbiome, each presenting their own set of challenges. However, recent advances in our understanding of the human microbiome have prompted a shift in corporate strategy, which could result in the approval of several microbiome-targeting therapeutics. That being said, the approval of these therapies will not come without challenges as pharmaceutical companies will need to establish this new class of therapy among physicians and convince payers of the advantages of their therapy over current treatment options.
In this expert presentation Alexandra Annis, MS, a Senior Healthcare Analyst at GlobalData, will share findings pulled from GlobalData’s Trend Report: Microbiome-Targeted Therapeutics in Immunology. The expert presentation will present key insights from KOLs and payers, including the most important challenges for pipeline therapies targeting the gut and skin microbiome, as well as the opportunities for companies developing microbiome-targeted therapeutics in immunology. Lakshmi Dharmarajan, PhD, Associate Director of Immunology at GlobalData, will moderate a Q&A session following the presentation.
Senior Healthcare Analyst, Immunology
Alexandra Annis, MS, is a Senior Analyst at GlobalData in Boston, covering Immunology. Prior to GlobalData, Alexandra received a BS in Health Sciences from Gettysburg College, and a MS in Chemistry from Boston College. She has over five years of research experience in chemistry and physiology in both academic and pharmaceutical laboratories at Gettysburg College, Boston College, and Sirtris, a GSK company. At Gettysburg, she studied the impact of the sirtuin pathway on the biological aging process, and while at Sirtris she synthesized small target molecules as developmental candidates for drugs to treat diseases of aging. As a graduate student, Alexandra specialized in the transformation of simple molecules into intermediates of biologically active compounds, with a thesis on the development of catalytic asymmetric methods to access alpha-chiral molecules.
Associate Director of Immunology
Lakshmi Dharmarajan, PhD, PPM, is the Associate Director of the Immunology team at GlobalData in Boston, where she manages the Immunology syndicated market research portfolio at GlobalData. Her team provides actionable insights to clients over a wide range of diseases including autoimmune, dermatological, gastrointestinal and niche orphan disorders. Lakshmi has over 6 years of experience in pharma market research and consulting, having worked with various clients across the healthcare industry. Lakshmi holds a Ph.D. in Biochemistry from Virginia Tech as well as a Masters in bioscience management from Keck Graduate Institute.
Key Learning Objectives
- Learn how GlobalData expects the epidemiology of acne vulgaris, atopic dermatitis, plaque psoriasis, Crohn's disease, ulcerative colitis, and irritable bowel syndrome to change between 2017 and 2022 across the 16 major markets.
- Gain insight on the late-stage pipeline for therapies targeting the gut and skin microbiome, including which products GlobalData expects to succeed, and why.
- Learn which unmet needs KOLs identified in the development of therapies targeting the gut and skin microbiome, and whether or not they are likely to be overcome in the near future.
- Learn about US payers’ perspectives on the pricing and reimbursement of therapies targeting the gut and skin microbiome.
- Senior Managers
- Associate Directors
- Directors of Market Research
- Business Insights
- Market Intelligence
- Strategic Insights
- Pipeline Management
- Competitive Strategy
- Customer Insights
- Heads of Research and Development
- Heads of Product Planning and Marketing
- Brand Managers